drugset / Trial / NCT00216554

The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania

NCT00216554

Phase 4 Completed 118 enrolled Janssen Korea, Ltd., Korea
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate effect of risperidone as a long-term combination therapy to mood stabilizers in the treatment of bipolar mania

Timeline

Start
2004-09
Primary completion
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Risperidone Other / unclassified 0.5 mg Oral
Subject Risperidone Other / unclassified 1 mg Oral
Subject Risperidone Other / unclassified 2 mg Oral

Indications